间接灸治疗过敏性鼻炎:随机对照试验系统评价与Meta分析
该系统评价纳入21项RCT共1549例过敏性鼻炎患者,评估间接灸单用或联合其他阳性干预的疗效与安全性。汇总分析显示总有效率、症状分级评分、TNSS及RQLQ均有显著改善,但VAS评分与血清IgE未见明显优势,证据质量总体偏低。
要点
- 间接灸可提高过敏性鼻炎总有效率(RR=1.16,95%CI=1.11-1.21),并改善症状评分与生活质量。
- 对VAS评分及血清IgE水平未见明显优势,不宜作为其主要疗效依据。
- 主要不良反应为烧伤与水疱,应用时需注意操作安全与皮肤防护。
核心结论
- 间接灸对过敏性鼻炎总体治疗可能具有较好临床效果并改善临床症状,但在改善VAS评分和血清IgE水平方面无明显优势。
- 因纳入文献样本量小、质量中等、证据等级低,结果需严格设计的RCT进一步验证。
研究设计与样本
- 系统评价与Meta分析,检索PubMed、Cochrane Library、Embase、Web of Science、CNKI、万方、维普及CBM至2020年5月22日。
- 纳入21项RCT共1549例过敏性鼻炎患者,其中5项采用间接灸单用、16项采用间接灸联合其他阳性干预。
- 采用Cochrane偏倚风险评估工具评价方法学质量,采用GRADE方法评级证据水平,用RevMan5.3.0进行Meta分析。
主要发现
- 总有效率RR=1.16(95%CI=1.11-1.21,I2=30%,P=0.10),差异有统计学意义。
- 症状分级评分SMD=-1.10(95%CI -1.58至-0.61,P<0.00001,I2=88%)、TNSS评分SMD=-1.36(95%CI -2.14至-0.58,P=0.76,I2=0%)、RQLQ量表SMD=-2.60(95%CI -4.06至-1.14,P<0.00001,I2=92%)均有显著差异。
- VAS评分SMD=-0.38(95%CI -1.06至0.30,P<0.003,I2=83%)无统计学意义。
- TNNSS与血清IgE仅各纳入1篇文献,行描述性分析:试验组降低TNNSS评分优于对照组(P<0.05),血清IgE两组无显著差异(P>0.05)。
关键数值与推荐
- 总有效率RR=1.16(95%CI=1.11-1.21,I2=30%,P=0.10)。
- 症状分级评分SMD=-1.10(95%CI -1.58至-0.61,P<0.00001,I2=88%)。
- TNSS评分SMD=-1.36(95%CI -2.14至-0.58,P=0.76,I2=0%)。
- RQLQ量表SMD=-2.60(95%CI -4.06至-1.14,P<0.00001,I2=92%)。
- VAS评分SMD=-0.38(95%CI -1.06至0.30,P<0.003,I2=83%)。
临床怎么用
- 可将间接灸作为过敏性鼻炎改善总体症状与生活质量的辅助手段,单用或联合西药等阳性干预均可考虑。
- 对以VAS评分或血清IgE为主要目标的患者,不应夸大间接灸的预期获益。
- 操作时注意防止烧伤与水疱,并依据证据质量低的现状向患者说明不确定性。
局限性
- 纳入文献样本量小、方法学质量中等、总体证据质量低。
- TNNSS与血清IgE仅各纳入1篇文献,仅作描述性分析。
- 部分结局指标异质性较高(如症状分级评分I2=88%、RQLQ I2=92%)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To synthesize the results of randomized clinical trials (RCTs) and evaluate the effectiveness and safety of indirect moxibustion for the treatment of allergic rhinitis (AR). METHODS: PubMed, the Cochrane Library, Embase, Web of Science, CNKI, WanFang, VIP, and CBM from the establishment to May 22, 2020 were searched. This was a PRISMA review. Reviewers identified studies, extracted data, and assessed the quality, independently. RCTs for AR patients treated with IM alone or IM combined with other positive interventions (e.g. western medicine, conventional therapy, etc.) were included. The main outcomes included: total effective rate and TNSS. The secondary outcomes included: TNNSS, Graded symptom score, RQLQ, VAS, Serum IgE level and adverse events. RCTs were collected, methodological quality was evaluated using the Cochrane risk-of-bias assessment tool (RoB), and the level of evidence was rated using the GRADE approach. Meta-analysis was performed using the RevMan5.3.0 manager. RESULTS: We included 21 RCTs involving 1549 patients. Five RCTs adopt IM treatment alone; 16 RCTs adopt IM+other positive interventions. In the assessment of the quality, the evidence differs from low to high based on the Cochrane Bias Evaluation Tools. Six trials were high quality, twelve were moderate quality, and three were low quality. Therefore, the quality of the included studies was moderate. The total evidence quality of all outcome indicators was low. The main adverse reactions of moxibustion are burns and blisters, whereas the western medicine group was nasal bleeding. The results of pooled analysis indicated a statistically significant effect in total effective rate of (RR=1.16, 95%CI=1.11-1.21, I2 =30%, P = 0.10). Besides, indirect moxibustion intervention also showed significant difference in graded symptom score (SMD=-1.10; 95% CI [-1.58, -0.61]; P < 0.00001; I2 =88%), TNSS score (SMD=-1.36; 95% CI [-2.14, -0.58]; P = 0.76; I2 =0%), and RQLQ scale (SMD=-2.60; 95% CI [-4.06, -1.14]; P < 0.00001; I2 =92%) in patients with AR. However, there was no statistical significance in VAS score (SMD=-0.38; 95% CI [-1.06, 0.30]; P < 0.003; I2 =83%). Since only one literature was included in TNNSS and Serum IgE levels, descriptive analysis was conducted.And the results showed that the trial group was better than the control group in reducing TNNSS score (P < 0.05). In serum IgE levels,there was no significant difference between the two groups (P > 0.05). CONCLUSION: From the analysis results, indirect moxibustion may have a good clinical effect on the overall treatment of AR, and improve the clinical symptoms of patients;but there was no obvious advantage in improving VAS score and Serum IgE level.Due to the limitations of small sample size, moderate quality and low level of evidence in the included literature, clinical trials should be designed in strict accordance with the standard of RCT in the future to verify this result.
引用
- Yuan T, Xiong J, Wang X, et al. Indirect moxibustion for the treatment of allergic rhinitis: A systematic review and meta-analysis of randomized controlled trials. Complement Ther Med. 2022. PMID: 35041988. doi:10.1016/j.ctim.2022.102804
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。